Inhibitors to Von Willebrand Factor in Type 3 Von Willebrand
Disease (VWD)
Hassan M Yaish1*, Robert Christiansen1, Jessica Meznarich1, Walid K Salah2, George Rodgers1 and Richard
Lemons1s
DOI: 10.26717/BJSTR.2017.01.000242
-
Author Information
Open or Close
- 1Department of Pediatrics, university of Utah, USA
- 2Duke University, USA
Corresponding author:
Hassan M Yaish, Department of Pediatrics, university of Utah, school of Medicine, Salt Lake City, UT 84113, USA
Received: July 20, 2017; Published: August 01, 2017
To view the Full Article Peer-reviewed Article PDF
Abstract
Type 3 VWD is the least common and most severe among the
three types of VWD. The incidence was estimated at 5-3/million
and the severity is thought to be similar to mild or moderate
hemophilia A. In a recent report from the UK showing that some
hemostasis laboratories may fail to perform all required assays for
the diagnosis of VWD Type 3, which occasionally result in giving a
wrong diagnosis such as mild or moderate hemophilia A. [1] Type
3 VWD is usually associated with a clinical course that combines
the bleeding features seen in patients with VWD as well as those
encountered in patients with mild to moderate hemophilia.
Introduction|
Objectives|
Methods|
Results|
Conclusion|
References|
ISSN: 2574 -1241
